The visual prognosis following HLA-matched keratoplasty for high-risk patients.
We report the clinical details of 30 HLA-matched corneal grafts with a mean follow-up of 29 months. Few of the patients were immunologically naive as almost all had received previous unmatched grafts. The two-year survival rate was 77%, comparable with other series. A majority of patients obtained good vision, and this was statistically superior to a recent large series. Almost all remained on their topical medication indefinitely. The contralateral visual acuity was surprisingly good, but there are few published data for comparison. We were unable to document an enhanced prognosis with a higher degree of HLA-A, B or DR match, possibly because of the small numbers.
Claoué
C
C
Moorfields Eye Hospital, London, U.K.
Buckley
R
R
Steele
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003315:Cornea / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006684:HLA-DR Antigens / Q000032:analysis; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D006650:Histocompatibility Testing; D006801:Humans; D015948:Keratoplasty, Penetrating / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014785:Vision, Ocular / Q000502:physiology*; D014792:Visual Acuity
D006684:HLA-DR Antigens; D015395:Histocompatibility Antigens Class I